The effects of carvedilol, metoprolol and propranolol on cisplatin-induced kidney injury

References

• Ajith, T.A., et al., 2009. Co-supplementation of single and multi doses of vitamins C and E ameliorates cisplatin-induced acute renal failure in mice. Experimental and Toxicologic Pathology: Official Journal of the Gesellschaft Fur Toxikologische Pathologie, 61 (6), 565–571.
   PubMedGoogle Scholar
• Arany, I., et al., 2004. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. American Journal of Physiology. Renal Physiology, 287 (3), F543–F549.
   PubMed Web of Science ®Google Scholar
• Baker, J.G., 2005. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. British Journal of Pharmacology, 144 (3), 317–322.
   PubMed Web of Science ®Google Scholar
• Benoehr, P., et al., 2005. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. Journal of the American Society of Nephrology, 16 (2), 452–458.
   PubMed Web of Science ®Google Scholar
• Cassidy, H., et al., 2012. The role of MAPK in drug-induced kidney injury. Journal of Signal Transduction, 2012, 463617.
   PubMedGoogle Scholar
• Chirino, Y.I., et al., 2008. Protective effects of apocynin against cisplatin-induced oxidative stress and nephrotoxicity. Toxicology, 245 (1–2), 18–23.
   PubMed Web of Science ®Google Scholar
• dos Santos, N.A., et al., 2012. Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Archives of Toxicology, 86 (8), 1233–1250.
   PubMed Web of Science ®Google Scholar
• El-Sayed el, S.M., Abd-Ellah, M.F., and Attia, S.M., 2008. Protective effect of captopril against cisplatin-induced nephrotoxicity in rats. Pakistan Journal of Pharmaceutical Sciences, 21 (3), 255–261.
   PubMed Web of Science ®Google Scholar
• Esmaeeli, A., et al., 2020., Low-dose angiotensin AT1 receptor β-arrestin-biased ligand, TRV027, protects against cisplatin-induced nephrotoxicity. Pharmacological Reports.
   Google Scholar
• Fatemikia, H., et al., 2017. Comparison of 99mTc-DMSA renal scintigraphy with biochemical and histopathological findings in animal models of acute kidney injury. Molecular and Cellular Biochemistry, 434 (1–2), 163–169.
   PubMed Web of Science ®Google Scholar
• Gomes, A., et al., 2006. Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species? Bioorganic & Medicinal Chemistry, 14 (13), 4568–4577.
   PubMed Web of Science ®Google Scholar
• Griffin, T.P., et al., 2016. A cross-sectional study of the effects of β-blocker therapy on the interpretation of the aldosterone/renin ratio: can dosing regimen predict effect? Journal of Hypertension, 34 (2), 307–315.
   PubMed Web of Science ®Google Scholar
• Healy, D.P., Münzel, P.A., and Insel, P.A., 1985. Localization of beta 1- and beta 2-adrenergic receptors in rat kidney by autoradiography. Circulation Research, 57 (2), 278–284.
   PubMed Web of Science ®Google Scholar
• Hultström, M., Becirovic-Agic, M., and Jönsson, S., 2018. Comparison of acute kidney injury of different etiology reveals in-common mechanisms of tissue damage. Physiological Genomics, 50 (3), 127–141.
   PubMed Web of Science ®Google Scholar
• Javadi, H., et al., 2010. The association of dipyridamole side effects with hemodynamic parameters, ECG findings, and scintigraphy outcomes. Journal of Nuclear Medicine Technology, 38 (3), 149–152.
   PubMedGoogle Scholar
• Kocak, C., et al., 2016. Effects of captopril, telmisartan and bardoxolone methyl (CDDO-Me) in ischemia-reperfusion-induced acute kidney injury in rats: an experimental comparative study. Clinical and Experimental Pharmacology and Physiology, 43 (2), 230–241.
   PubMed Web of Science ®Google Scholar
• Komaki, K., et al., 2017. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study. BMC Cancer, 17 (1), 144.
   PubMed Web of Science ®Google Scholar
• Koukourakis, M.I., 2002. Amifostine in clinical oncology: current use and future applications. Anticancer Drugs, 13 (3), 181–209.
   PubMed Web of Science ®Google Scholar
• Kroning, R., Lichtenstein, A.K., and Nagami, G.T., 2000. Sulfur-containing amino acids decrease cisplatin cytotoxicity and uptake in renal tubule epithelial cell lines. Cancer Chemotherapy and Pharmacology, 45 (1), 43–49.
   PubMed Web of Science ®Google Scholar
• Mizuno, T., et al., 2016. Lower blood pressure-induced renal hypoperfusion promotes cisplatin-induced nephrotoxicity. Oncology, 90 (6), 313–320.
   PubMed Web of Science ®Google Scholar
• Mohana Lakshmi, S., Kiran Reddy, U.T., and Sandhya Rani, K.S., 2012. A review on medicinal plants for nephroprotective activity. Asian Journal of Pharmaceutical and Clinical Research, 5 (4), 8–14.
   Google Scholar
• Mukhopadhyay, P., et al., 2016. The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity. British Journal of Pharmacology, 173 (3), 446–458.
   PubMed Web of Science ®Google Scholar
• Noor, N., Patel, C.B., and Rockman, H.A., 2011. Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. Journal of Molecular and Cellular Cardiology, 51 (4), 534–541.
   PubMed Web of Science ®Google Scholar
• Ó hAinmhire, E., and Humphreys, B.D., 2017. Fibrotic changes mediating acute kidney injury to chronic kidney disease transition. Nephron, 137 (4), 264–267.
   PubMed Web of Science ®Google Scholar
• Okui, S., et al., 2012. Cisplatin-induced acute renal failure in mice is mediated by chymase-activated angiotensin-aldosterone system and interleukin-18. European Journal of Pharmacology, 685 (1–3), 149–155.
   PubMed Web of Science ®Google Scholar
• Pabla, N., and Dong, Z., 2008. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney International, 73 (9), 994–1007.
   PubMed Web of Science ®Google Scholar
• Peters, A.M., et al., 1988. Two routes for 99mTc-DMSA uptake into the renal cortical tubular cell. European Journal of Nuclear Medicine, 14 (11), 555–561.
   PubMedGoogle Scholar
• Peterson, Y.K., and Luttrell, L.M., 2017. The diverse roles of arrestin scaffolds in G protein–coupled receptor signaling. Pharmacological Reviews, 69 (3), 256–297.
   PubMed Web of Science ®Google Scholar
• Pippin, J.W., et al., 2003. DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. Journal of Clinical Investigation, 111 (6), 877–885.
   PubMed Web of Science ®Google Scholar
• Riazi, A., et al., 2014. Technetium-99m methoxyisobutylisonitrile scintigraphy in the assessment of cold thyroid nodules: is it time to change the approach to the management of cold thyroid nodules? Nuclear Medicine Communications, 35 (1), 51–57.
   PubMed Web of Science ®Google Scholar
• Rodrigues, M.A., et al., 2010. Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats. Mitochondrion, 10 (1), 46–53.
   PubMed Web of Science ®Google Scholar
• Rodrigues, M.A.C., et al., 2011. Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria. Chemico-Biological Interactions, 189 (1–2), 45–51.
   PubMed Web of Science ®Google Scholar
• Saleh, S., et al., 2009. Protective effects of the angiotensin ii receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy, 55 (6), 399–406.
   PubMed Web of Science ®Google Scholar
• Saleh, S., and El-Demerdash, E., 2005. Protective effects of L-arginine against cisplatin-induced renal oxidative stress and toxicity: role of nitric oxide. Basic & Clinical Pharmacology & Toxicology, 97 (2), 91–97.
   PubMed Web of Science ®Google Scholar
• Sener, G., et al., 2000. The protective effect of melatonin on cisplatin nephrotoxicity. Fundamental & Clinical Pharmacology, 14 (6), 553–560.
   PubMed Web of Science ®Google Scholar
• Seyedabadi, M., Ghahremani, M.H., and Albert, P.R., 2019. Biased signaling of G protein coupled receptors (GPCRs): molecular determinants of GPCR/transducer selectivity and therapeutic potential. Pharmacology & Therapeutics, 200, 148–178.
   PubMed Web of Science ®Google Scholar
• Seyedabadi, M., et al., 2012. Ser/Thr residues at α3/β5 loop of Gαs are important in morphine-induced adenylyl cyclase sensitization but not mitogen-activated protein kinase phosphorylation. FEBS Journal, 279 (4), 650–660.
   PubMed Web of Science ®Google Scholar
• Seyedabadi, M., Rahimian, R., and Ghia, J.-E.J.E., 2018. The role of alpha7 nicotinic acetylcholine receptors in inflammatory bowel disease: involvement of different cellular pathways. Expert Opinion on Therapeutic Targets, 22 (2), 161–176.
   PubMed Web of Science ®Google Scholar
• Sheikh-Hamad, D., Timmins, K., and Jalali, Z., 1997. Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. Journal of the American Society of Nephrology, 8 (10), 1640–1644.
   PubMed Web of Science ®Google Scholar
• Tanha, K., et al., 2017. Assessment of the maximum uptake time of 99mTc-DMSA in renal scintigraphy in rat. Iranian Journal of Nuclear Medicine, 25 (2), 110–114.
   Web of Science ®Google Scholar
• Thanawala, V.J., et al., 2014. Ligand bias prevents class equality among beta-blockers. Current Opinion in Pharmacology, 16, 50–57.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2017. β-Arrestin-biased AT1R stimulation promotes extracellular matrix synthesis in renal fibrosis. American Journal of Physiology. Renal Physiology, 313 (1), F1–F8.
   PubMed Web of Science ®Google Scholar
• Wisler, J.W., et al., 2007. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proceedings of the National Academy of Sciences of the United States of America, 104 (42), 16657–16662.
   PubMed Web of Science ®Google Scholar
• Yao, X., et al., 2007. Cisplatin nephrotoxicity: a review. The American Journal of the Medical Sciences, 334 (2), 115–124.
   PubMed Web of Science ®Google Scholar
• Yue, T.L., et al., 1992. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. The Journal of Pharmacology and Experimental Therapeutics, 263 (1), 92–98.
   PubMed Web of Science ®Google Scholar
• Yürekli, Y., et al., 2011. L-carnitine protection against cisplatin nephrotoxicity in rats: Comparison with amifostin using quantitative renal Tc 99m DMSA uptake. Molecular Imaging and Radionuclide Therapy, 20 (1), 1–6.
   PubMedGoogle Scholar
• Yuwen, D., et al., 2017. Andrographolide enhances cisplatin-mediated anticancer effects in lung cancer cells through blockade of autophagy. Anti-Cancer Drugs, 28 (9), 967–976.
   PubMed Web of Science ®Google Scholar
• Zuk, A., and Bonventre, J.V., 2016. Acute kidney injury. Annual Review of Medicine, 67 (1), 293–307.
   PubMed Web of Science ®Google Scholar